Market Signal Briefing

The stablecoin will facilitate tokenized asset transactions and is expected to be linked to the Brazilian real. Dec 17, 2025, 8:03 p.m.

Brazil’s main stock exchange B3 is planning on deepening its involvement in the cryptocurrency space through the launch of a tokenization platform and its own stablecoin next year.

The tokenization platform is set to allow assets to be tokenized and traded on the exchange, with Luiz Masagão ,B3’s vice president of products and clients, saying both systems will share the same liquidity pool.

STORY CONTINUES BELOW

"The token buyer won't know they are buying from a traditional stock seller,” Masagão added. “This allows for a smooth transition, with both systems using the same liquidity."

To support settlement, B3 also plans to issue a stablecoin. It would serve as a payment and clearing tool inside the tokenized environment, reducing reliance on existing cash processes.

"We are also going to launch a B3 stablecoin, which will serve as a tool to enable token trading,” Masagão said. The stablecoin is expected to be linked to the Brazilian real.

B3 is also expanding crypto-linked derivatives. Products under development include weekly options on bitcoin, ether and solana, along with event-based contracts tied to crypto prices. These instruments are currently under review by Brazil’s securities regulator, the CVM.

The exchange has spent the past several years building crypto exposure through listed products and includes offerings tied to BTC, ETH, SOL, and crypto indices. It first listed a crypto ETF back in April 2021, years before the U.S.

These products are held by roughly 600,000 investors and account for about $2.4 billion in assets under management, according to the exchange. Earlier this month, asset manager Valour listed four newETPs on the exchange.

The real-world asset (RWA) market has grown to top $18 billion this year, according to RWA.xyz, with most tokenized assets being commodities and U.S. Treasury debt.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

Most Influential: Carlos Domingo

6 hours ago

The Securitize CEO ground through the uncool years of tokenization while NFTs, FTX and memecoins soaked up the hype. With billions in tokenized assets, a SPAC listing in the works and BlackRock as a flagship client and backer, Carlos Domingo’s early bet is finally paying off.

Read full story

On today's episode of CNBC Crypto World, bitcoin falls as Wall Street rethinks some AI investments. Also, CF Benchmarks CEO Sui Chung discusses recent trends in crypto ETFs.

TL;DR

Binance Wallet integrates DeFi loans via Venus Protocol for self-custody borrowing.
Allows loans against BTC/ETH without selling, avoiding taxable sale events.
Features a 400,000 USDT reward pool to attract initial borrowers.

Binance expands lending and adds DeFi loans inside Binance Wallet through a partnership with Venus Protocol. The feature runs in a self-custody wallet and targets users who want liquidity without selling core holdings. Binance also announced a 400,000 USDT reward pool for eligible borrowers.

The rollout follows Binance’s recent push in lending on the centralized platform, where an institutional loan program offers terms aimed at high-net-worth clients, including up to 4x exposure and, in some cases, zero-interest conditions. Binance now brings a loan flow into Web3 and places borrowing inside the wallet interface.

Introducing Web3 Loan on #Binance Wallet 🚀
Borrow crypto on-chain using your existing assets as collateral.

Unlock liquidity, explore new earning opportunities, and manage everything seamlessly in one place.

Learn More 👉https://t.co/FYSmXkXUoX pic.twitter.com/FfXxb7qAeS

— Binance Wallet (@BinanceWallet) December 17, 2025

This lands in a market where Ethereum protocols control about 80% of DeFi lending share. Aave stands as the largest single player and controls about 60% of DeFi lending, based on market-share estimates cited in industry data.

Binance Wallet adds Venus Protocol loans and pays rewards in USDT
Binance says users of Binance Wallet can access DeFi loans via Venus Protocol, the largest lending platform on the BNB network. Venus reports more than $22 billion in liquidity in public figures linked to the product launch. Under the setup, a user deposits collateral and opens a loan while keeping control of assets inside the wallet.

The entry point sits on the Web3 Earn page in Binance Wallet
A borrower can post collateral such as Bitcoin and Ethereum and receive liquidity for trading or yield-driven activity. The structure avoids a spot sale of the underlying asset, a detail some users track closely because asset sales can trigger taxes in jurisdictions such as the United States.

Binance serves more than 240 million users worldwide, which creates a distribution edge in a lending market that exceeded $54 billion in total value locked across DeFi lending platforms by mid-2025, based on sector estimates. 

Source: DeFiLlama
The BNB network also posts more than $17 billion in DeFi total value locked, a base that supports Binance’s push with lower fees and faster confirmation times than many Ethereum-based routes.

Ethereum still sets the pace through scale and liquidity. Aave, MakerDAO, and Compound hold about 72% of DeFi lending share across major venues. Aave also grew TVL by 52% in Q2 2025, outpacing broader DeFi growth of 26% over the same period, according to market tracking referenced in the data. Aave operates across 14 networks and processes billions in flash loans and cross-chain transactions each month in commonly cited reporting.

Binance aims to win users on cost and ease of use
Other chains already show migration when fees fall and performance improves. Solana holds about 5.1% of DeFi deposits in cited market splits, which supports the idea that users switch venues for lower costs.

Market metrics also point to room for challengers despite Ethereum’s lead. DeFi lending counts more than 7.8 million users in reported figures. The segment also rose about 38%, from $19.1 billion in 2024 to more than $26 billion by mid-2025, according to the same dataset.

Binance now puts a new product in front of wallet users: DeFi loans backed by BTC and ETH, routed through Venus Protocol, and paired with USDT rewards. The market now watches one outcome: user adoption levels in a lending arena where Ethereum still carries most of the volume.

The world's second-largest cryptocurrency isn't feeling the love from investors today.

Broad market weakness is once again bleeding into valuations in the cryptocurrency sector. The world's second-largest token is also on the decline today, with Ethereum (ETH 4.31%) slumping 4.7% over the past 24 hours, as of 2:45 p.m. ET. This move has brought Ethereum back toward the $2,800 range, after briefly spiking above $3,000 again this morning.

Today's Change

(

-4.31

%) $

-126.91

Current Price

$

2818.72

With so much attention now centered on whether Ethereum can maintain momentum above the $3,000 level, today's price action highlights some broader structural weakness in the crypto sector worth noting.

Let's dive into exactly what's moving the needle for Ethereum right now, given its otherwise bullish backdrop.

What gives?

Source: Getty Images.

Ethereum's decline today comes amid some strong catalysts that investors might think would lead to price appreciation in any other period. I've touched on some of these upside catalysts recently, including a tokenized money market fund launched by JPMorgan on this network (https://www.theblock.co/post/382504/jpmorgan-launches-tokenized-money market-fund-ethereum) and BitMine's Tom Lee reiterating his bullish narrative around the future of this layer-1 network as a long-term buying opportunity at current levels.

However, weakening risk sentiment around Ethereum and other top cryptocurrencies today has led to sharp swings in both directions. This has resulted in liquidation activity picking up for both long and short positions, with more than $162 million of Ethereum perpetual futures derivatives contracts liquidated over the past day ($130 million of which was on the long side).

This indicates to investors that any significant near-term price swing in Ethereum could be exacerbated, as more and more on-chain trading activity for top tokens shifts to the derivatives market.

Overarching broader market weakness, tied to a weaker-than-expected jobs report for the past two months released yesterday, appears to be the straw that broke the back of market sentiment. I'd reckon we could see continued highly volatile swings moving forward based on new economic data releases as they come-that's been the standard thus far this year.

Chris MacDonald has positions in Ethereum. The Motley Fool has positions in and recommends Ethereum. The Motley Fool has a disclosure policy.

Key points:

Bitcoin failed to hold above $90,000, indicating a lack of demand at higher levels.

Several major altcoins started a recovery, but the higher levels attracted solid selling pressure from the bears.

Bitcoin (BTC) bulls pushed the price above $90,000 on Wednesday, but higher levels attracted selling by the bears. Spot BTC exchange-traded funds have recorded outflows of $634.8 million this week, according to Farside Investors data, indicating a cautious approach by institutional investors.

CryptoQuant analyst MorenoDV_ said in a recent Quicktake analysis that the True Market Mean (TMM), which represents the cost basis of all non-dormant coins, excluding miners, acts “like a psychological line in sand.” If the TMM, currently at $81,500, cracks, BTC could fall sharply, searching for support in the coming months.

Crypto market data daily view. Source: TradingViewAt the other end of the spectrum are Grayscale analysts, who remain optimistic about 2026. In its 2026 outlook report, Grayscale said that BTC could reach a new all-time high in the first half of the next year on the back of macro tailwinds and better regulatory clarity in the US.

What are the crucial support and resistance levels to watch out for in BTC and major altcoins? Let’s analyze the charts of the top 10 cryptocurrencies to find out.

Bitcoin price predictionBuyers pushed BTC back above the uptrend line on Wednesday, but the long wick on the candlestick shows selling at higher levels. 

BTC/USDT daily chart. Source: Cointelegraph/TradingViewThe bears will try to pull the Bitcoin price below the $84,000 support. If they manage to do that, the BTC/USDT pair could retest the crucial level at $80,600. Buyers are expected to fiercely defend the $80,600 to $73,777 zone.

The first sign of strength will be a break and close above the 20-day exponential moving average ($90,037). The pair could then climb to $94,589 and subsequently to the psychological level of $100,000.

Ether price predictionEther (ETH) rebounded off the uptrend line on Tuesday, but the recovery stalled at the 20-day EMA ($3,066) on Wednesday.

ETH/USDT daily chart. Source: Cointelegraph/TradingViewThe bears are attempting to strengthen their position by pulling the Ether price below the uptrend line. If they manage to do that, the ETH/USDT pair could drop to $2,716 and then to $2,623.

Buyers have an uphill task ahead of them. They will have to drive the Ether price above the $3,350 resistance to signal a potential trend change in the near term. That opens the doors for a rally to $3,659 and then to $3,918.

BNB price predictionBuyers tried to push BNB (BNB) back above the 20-day EMA ($883), but the bears successfully defended the level.

BNB/USDT daily chart. Source: Cointelegraph/TradingViewThe sellers will try to pull the BNB price below the $840 level and test the critical support at $791. Buyers are expected to defend the $791 level with all their might, as a break below it could sink the BNB/USDT pair to $730.

Instead, if the price turns up and breaks above the moving averages, it suggests that the pair could remain range-bound between $791 and $1,020 for some time. Buyers will be back in the driver’s seat on a close above $1,020.

XRP price predictionXRP (XRP) has been sliding toward the support line of the descending channel pattern, indicating a negative sentiment. 

XRP/USDT daily chart. Source: Cointelegraph/TradingViewThe bulls are expected to mount a strong defense in the zone between the support line of the channel and $1.61. Any relief rally is likely to face selling at the 20-day EMA ($2.03) and then at the 50-day simple moving average ($2.18).

If the XRP price turns down from the moving averages, the possibility of a break below $1.61 increases. The XRP/USDT pair could then plummet to the Oct. 10 low of $1.25. On the other hand, a break above the downtrend line signals a potential trend change.

Solana price predictionThe bulls are trying to defend the support line in Solana (SOL), but the weak bounce suggests the bears continue to exert pressure.

SOL/USDT daily chart. Source: Cointelegraph/TradingViewThe downsloping 20-day EMA ($133) and the relative strength index (RSI) below 39 signal that the bears are in control. A close below the support line indicates the continuation of the downward move. The SOL/USDT pair could plunge to $110 and then to the solid support at $95, where the buyers are expected to step in.

The bulls will have to push and maintain the Solana price above the resistance line to gain the upper hand. The pair could then rally to $172.

Dogecoin price predictionDogecoin (DOGE) fell below the $0.13 support on Monday, signaling the resumption of the downtrend.

DOGE/USDT daily chart. Source: Cointelegraph/TradingViewA minor advantage for the bulls is that the RSI is forming a positive divergence. That suggests the selling pressure is reducing. Buyers will have to swiftly push and sustain the Dogecoin price above the 50-day SMA ($0.15) to signal strength. The DOGE/USDT pair may then ascend to $0.19.

Alternatively, if the price continues lower or turns down from $0.14, it suggests that the bears remain in command. The pair may then tumble to the Oct. 10 low of $0.10.

Cardano price predictionCardano (ADA) is struggling to bounce off the $0.37 support, indicating a lack of aggressive buying by the bulls.

ADA/USDT daily chart. Source: Cointelegraph/TradingViewSellers will try to strengthen their position by pulling the Cardano price below the $0.37 level. If they can pull it off, the ADA/USDT pair could plunge to $0.32 and then to the Oct. 10 low of $0.27.

Any relief rally is expected to face selling at the moving averages. The bulls will have to propel and maintain the price above the breakdown level of $0.50 to signal a comeback. The pair may then rally to $0.61.

Bitcoin Cash price predictionBitcoin Cash (BCH) bounced off the 50-day SMA ($534) on Tuesday, and the bulls are attempting to sustain the price above the 20-day EMA ($558) on Wednesday.

BCH/USDT daily chart. Source: Cointelegraph/TradingViewIf the price fails to maintain above the 20-day EMA, the sellers will again attempt to pull the BCH/USDT pair below the 50-day SMA. If they succeed, the Bitcoin Cash price may dip below the $508 support. That suggests a range-bound action between $443 and $615 for some more time.

Contrarily, if the price closes above the 20-day EMA, it signals a positive sentiment. The bulls will then attempt to push the pair to the overhead resistance at $615. 

Hyperliquid price predictionBuyers are attempting to start a recovery in Hyperliquid (HYPE), but it is likely to face selling near the 20-day EMA ($30.26).

HYPE/USDT daily chart. Source: Cointelegraph/TradingViewIf the price turns down from the 20-day EMA, the HYPE/USDT pair may resume its downtrend. The pair may decline to $24 and then to the Oct. 10 low of $20.82.

Contrary to this assumption, if the price turns up and breaks above the 20-day EMA, it suggests that the selling pressure is reducing. The pair may then climb to the breakdown level of $35.50, which is a critical level to watch out for. If buyers overcome the resistance, it indicates that the downtrend could be over.

Chainlink price predictionChainlink (LINK) has been trading below the moving averages, increasing the likelihood of a drop to the $10.94 support.

LINK/USDT daily chart. Source: Cointelegraph/TradingViewBuyers are expected to vigorously defend the $10.94 level, but the relief rally may face selling at the moving averages. If the price turns down from the moving averages, the LINK/USDT pair could dive to the Oct. 10 low of $7.90.

Contrary to this assumption, if the Chainlink price turns up from the current level or the $10.94 support and breaks above $15, it signals demand at lower levels. The pair could then rally to $16.80. 

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

It's not just sentiment that's declining for Dogecoin today.

Dogecoin (DOGE 4.44%) is one of the quickest decliners in a very red cryptocurrency market today. This token has declined 4.5% over the past 24 hours, as of 3:15 p.m. ET, despite bouncing off an intraday low that had brought this top meme coin down by more than 5%.

Today's Change

(

-4.44

%) $

-0.01

Current Price

$

0.13

Even for a meme coin, I'd argue that this move is substantial. That's because Dogecoin is still the ninth-largest cryptocurrency by market capitalization and is widely considered a fairly accurate sentiment gauge for digital assets more broadly.

Let's dive into what may have shifted with Dogecoin's investment thesis today, or if this is another run-of-the-mill market sell-off investors shouldn't pay too much attention to.

Market weakness isn't the only story for Dogecoin today

Source: Getty Images.

Yes, broader market weakness is something we need to factor into our analysis of today's dismal performance for Dogecoin. The wider cryptocurrency market declined by 2.9% over the past day, so about half of Dogecoin's move can likely be explained by broad-based selling pressure.

Much of this weakening sentiment can be attributed to yesterday's jobs report, which showed the U.S. unemployment rate surging yet again in November to 4.6%, its sixth consecutive month of 0.1% increases, and the highest unemployment level in years. Off of this year's low in January of 4% and a 4.1% level in June, that's a significant move. If we do see unemployment continue to rise, concerns about the availability of speculative capital to flow into tokens like Dogecoin are indeed meaningful.

Despite large investors scooping up 138 million DOGE tokens yesterday, investors appear to be paying closer attention to the weakening fundamentals around active monthly users and Dogecoin's total value locked (TVL). Both metrics have continued to decline, with monthly active users near the lowest levels we've seen in roughly six months, and Dogecoin's TVL sinking from around $26 million in September to under $13 million today.

Those are numbers that suggest previously robust user growth and invested capital within the Dogecoin ecosystem are deteriorating. In other words, Dogecoin's move today may have more to do with its own fundamentals than its use as a gauge of market sentiment.

Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

XRP’s spot ETFs are sucking in roughly $50 million a day in fresh capital, hitting nearly $1 billion in inflows in under four weeks, the fastest adoption pace since Ethereum ETFs launched.

Yet the token itself has cratered 11% over the past ten days and sits near $1.72, well below the $2.00 psychological support that the market has been watching.

The divergence reveals something important about how institutional money actually flows into crypto and why on-chain buying pressure doesn’t always translate into immediate price support.

The story matters because it forces a reckoning with how modern crypto markets work.

ETF inflows can signal long-term institutional conviction, but they don’t guarantee short-term price lifts.

Understanding the gap between the two is crucial for investors trying to figure out whether XRP is being accumulated on weakness or simply trapped in a bearish technical pattern that no amount of institutional dry powder can reverse.

ETF demand grows, but why XRP price following?
Copy link to section

Spot XRP ETFs launched barely three weeks ago with Franklin Templeton, Grayscale, and Bitwise leading the charge.

Since inception, they’ve racked up roughly $1 billion in net inflows spread across 20 consecutive trading days.

For context, that absorption rate rivals what Bitcoin and Ethereum ETFs saw in their first months, signaling that Wall Street’s appetite for regulated crypto exposure remains robust.

But here’s the wrinkle: ETF inflows don’t automatically move the spot price higher.

The mechanics are more subtle. When you buy an XRP ETF, authorized participants, large trading firms that sit between you and the underlying market, either deliver XRP they already own from inventory or source it through their existing hedges.

Many of these firms hedge their long ETF positions by simultaneously shorting XRP derivatives or selling it in spot markets to neutralize risk.

That hedging pressure can easily offset the upside from institutional demand flowing through the ETF, leaving the price stuck or even under pressure.

The timing lag matters too. ETF inflows take days to settle and clear.

During that window, derivatives traders and high-frequency algorithms often front-run the flows, causing price spikes that reverse once the actual capital lands.

By the time the dust settles, much of the inflow’s bullish impact has already been priced in and sold into.

The structural reality
Copy link to section

The redemption mechanism was supposed to keep ETF prices glued to spot prices through arbitrage.

And it does, the spreads are tight. But that same mechanism can act as a pressure valve for sellers.

When XRP’s spot price weakens on technical selling or macro sentiment, market makers have no reason to keep buying expensive inventory to feed the ETF creation machine.

They step back. Meanwhile, holders who panic-sold XRP in spot markets did so before the ETF inflows even arrived to support prices. Add to that a tougher macro backdrop.

Bitcoin and Ethereum have also pulled back recently, taking the broader crypto risk asset bid with them.

Hedge funds and CTA funds that were long XRP derivatives ahead of the ETF launch have been trimming positions at losses.

That forced selling in leveraged markets can overwhelm any structural bid from slow-moving institutional ETF inflows.

The on-chain data tells the story clearly: XRP exchange balances have fallen 45% over two months as holders moved tokens into private wallets and custody.

But that doesn’t mean prices rise immediately. Supply tightening usually precedes rallies by weeks or months.

The Bottom Line XRP ETF inflows are real and represent genuine institutional buying interest. But they’re not a price-support floor in the short term.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Recent fund flow data across US-listed crypto investment products is revealing a notable divergence in investor behavior, as Ethereum-focused funds continue to shed billions in capital, and XRP-linked products are recording steady inflows that now place them among the strongest performers in the Spot crypto ETF market. 

Data from SoSoValue shows that this divergence has persisted for the past month, showing that investors are beginning to favor XRP’s regulated crypto exposure over Ethereum.

Ethereum ETFs See Billions Exit In One Month
According to SoSoValue data, Ethereum Spot ETFs have experienced sustained capital outflows over the past four weeks, with cumulative net outflows since the beginning of November coming in at $1.725 billion. November alone accounted for $1.42 billion of those redemptions, making it the worst month for Ethereum ETF flows since the products launched in the US in July 2024.

The intensity of the selling was evident across several trading sessions during November, where  daily outflows exceeded $250 million on a few occasions. This negative momentum has carried into December with little sign of stabilization. Spot Ethereum ETFs have extended their outflow streak, with the most recent two trading days alone recording net redemptions of $224.78 million and $224.26 million, respectively. 

At the same time, Ethereum’s Spot price has struggled to gain traction. The continued ETF outflows have coincided with muted price action, with ETH failing to hold above $3,000.

Rather than seeing rotation between Ethereum products, the data shows capital leaving the Ethereum ETF complex altogether. This pattern means that investors may be reallocating funds away from ETH exposure into other assets, and XRP is showing the strongest conviction.

Spot Ethereum ETF Flows. Source: SoSoValue

XRP ETFs Record $1 Billion In Consistent Inflows
The first U.S.-listed Spot XRP ETF was launched on November 23, and the momentum has been positive since then. At the time of writing, there are now five Spot XRP ETF issuers in the US, and they have yet to have a collective day of outflows. 

In contrast, XRP-linked spot ETFs have posted a full month of uninterrupted net inflows. This comes up to 22 consecutive trading days, with a cumulative inflow of $1.01 billion since launch. This, in turn, has pushed total assets under management to around $1.16 billion as of December 16. 

Spot XRP ETF Flows. Source: SoSoValue

Ripple CEO Brad Garlinghouse described the growth of XRP ETFs as a signal of broader structural demand for regulated crypto products. He recently highlighted that XRP became the fastest crypto spot ETF since Ethereum to surpass $1 billion in assets under management in the US. This shows institutional crypto investors are switching sides from Ethereum to XRP. 

The divergence becomes even more pronounced when compared with Bitcoin, which has always dictated the pace of general inflows. According to data from SoSoValue, Spot Bitcoin ETFs are on a combined outflow of $3.915 billion since the beginning of November.

Spot Bitcoin ETF Flows. Source: SoSoValue

What makes these numbers more interesting is that they are coming at a period of bearish price action for the entire crypto market, with the XRP price even breaking below the $2 support level. 

Price pushes lower with pressure | Source: XRPUSDT on Tradingview.com
Featured image created with Dall.E, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

flash news

Wrapped Bitcoin Launches on Hedera With BitGo Support, Expanding DeFi Access

Hedera confirmed the launch of Wrapped Bitcoin (WBTC) on its network, supported by custodian BitGo, enabling BTC holders to access Hedera-based DeFi without selling their

Hedera News

Hashgraph Group and PwC Launch Hedera-Powered ESG Solutions for Global Enterprises

TL;DR The Hashgraph Group partners with PwC Switzerland and PwC Germany to deploy Hedera-powered ESG solutions that enhance transparency and auditability in sustainability reporting. Their

CryptoCurrency News

HBAR Market Cap Jumps 43% in Q3 2025 as Hedera Ecosystem Expands

TL;DR HBAR’s market capitalization surged 43% in Q3 2025, reaching $9.1 billion, while its token price climbed 43.2% to $0.21. Hedera’s DeFi ecosystem strengthened, with

Price Analysis

$HBAR Technical Analysis: Mixed Signals Between Technical Recovery and Further Downside Risk

The trend remains clearly bearish, with the price still respecting the descending trendline that began on July 27 after an accumulated drop of nearly 48%.

Technology

Hedera Strengthens Transparency With Google BigQuery Integration

TL;DR Hedera Hashgraph has been integrated into Google BigQuery public datasets, allowing developers and enterprises to access the full transaction history. The inclusion enables cross-chain

CryptoCurrency News

Institutional Momentum Fuels HBAR Surge as Market Eyes Long-Term Growth

TL;DR The cryptocurrency HBAR surged over 10 % in the last 24 hours to around $0.1914, reflecting a strong inflow of institutional capital. Its market capitalization stands

Bitcoin trades near $89,000 today after its 14-day relative strength index fell below 30 in mid-November, a threshold traders track for capitulation.

A chart circulated by Global Macro Investor’s Julien Bittel, sourced to LSEG Datastream, overlays Bitcoin’s recent path with the average trajectory that followed the last five RSI breaks below 30 and traces a route that ends near $180,000 about 90 days after the oversold print.

The $180,000 waypoint is return math. With Bitcoin near $89,000, reaching $180,000 would imply a roughly 105% gain in roughly three months, or about 0.80% compounded daily.

The chart isn't a forecast distribution but an event-study average, meaning it can mask how different the paths were across those five historical instances.

Bitcoin oversold RSI projections (Source: Julien Bittel)Doomer evidence for the four year cycle and market topPrice action since October has kept the “cycle” argument active. Bitcoin set an October high at $126,223, then sold off into late November.

The decline reached a low near $80,697 on Nov. 21, a drawdown of about 36% from the October high.

That drop already sits inside the 35% to 55% drawdown band laid out in CryptoSlate’s cycle-timing framing, which mapped a trough zone of roughly $82,000 to $57,000 if the post-halving cadence remains the governing model.

Time is up: The case for why Bitcoin bear market cycle started at $126k

A second CryptoSlate analysis focused on $106,400 as a balance point that repeatedly flipped between support and resistance.

Bull or bear? Today's $106k retest decided Bitcoin's fate

Bitcoin has spent weeks below that level into mid-December, which matters for the RSI chart because a move toward $180,000 would almost certainly require acceptance above prior regime pivots rather than only a momentum bounce inside a corrective range.

Flows are a practical cross-check on whether the bounce thesis has fuel. Investors pulled a record $523 million from BlackRock’s iShares Bitcoin Trust (IBIT) on Nov. 19 as Bitcoin slipped below $90,000, and net ETF inflows have all but flatlined since.

Derivatives positioning adds another constraint: where the market is paying for optionality and where dealer hedging can keep spot in a band.

A CryptoSlate report on the options complex put dealer gamma concentration placed it in a broad $86,000 to $110,000 range, a range that can promote two-way trade as hedges are adjusted and can delay trend moves until spot exits with follow-through.

Bitcoin’s $55 billion options market is now obsessing over one specific date that forces a $100k showdown

Per Barchart’s technical dashboard, Bitcoin’s 14-day RSI has mean-reverted to around 40 after the mid-November sub-30 reading, which fits a bounce, while leaving the market sensitive to any renewed selling pressure if flows weaken again.

Is the 4-year cycle dead?Bittel’s “four-year cycle is dead” claim rests on macro mechanics rather than halving calendars. He ties cycle timing to public-debt refinancing dynamics and the maturity profile of U.S. borrowing, then connects that to interest expense as a driver of policy and liquidity responses.

Federal Reserve Economic Data (FRED) tracks federal government interest payments as a line item in current expenditures, and, according to the Committee for a Responsible Federal Budget, interest on the debt is projected to exceed $1 trillion annually.

Liquidity conditions are also central to the 90-day window because the RSI chart’s horizon overlaps with macro lead-lag narratives that traders already use.

The Federal Reserve cut rates to a 3.50% to 3.75% range in December and also announced about $40 billion per month in short-dated Treasury bill purchases (plus reinvestments) aimed at calming year-end funding pressures.

A version of global M2 liquidity shifted by about 90 days is often plotted against Bitcoin to illustrate how liquidity impulses can precede risk-asset repricing, even though the relationship can decouple for long stretches.

Bitcoin to M2 (84d lag) correlation over 180 daysMy analysis of the M2 correlation, adjusted by exactly 84 days, concludes that during moves up, the M2 line tracks the Bitcoin price path. However, during a downswing, M2 keeps grinding higher while the price diverges.

Bitcoin vs M2 and liquidityThe counterweight is that RSI can remain extreme and still fail to mark a lasting low.

In practice, that turns the $180,000 path into a gated setup where confirmations matter more than the fact of an RSI breach.

CheckpointLevel or metricHow it is being usedStarting level~$87,800 (Dec. 17)Base for the 90-day return mathEvent trigger14-day RSI below 30 (mid-Nov.)Defines t=0 for the RSI event windowChart target~$180,000 by about +90 daysImplied move of ~+105%Regime pivot$106,400Reclaim and hold to shift from bounce to trendDealer band$86,000 to $110,000Acceptance outside the band to reduce range-trade pressureFlow stress marker~-$523M IBIT day (Nov. 19)Benchmark for risk-off flow shocks (per Reuters, Farside Investors)Cycle drawdown band$82,000 to $57,000 zoneArea mapped from the $126,223 peak in the cycle-valid frameworkBitcoin has already produced the inputs this debate relies on: the mid-November RSI break, and the Nov. 21 low near $80,697, leaving $106,400 and daily spot ETF flows as the clearest markers for whether the rebound remains a bounce or extends toward the chart’s $180,000 path.

Still, analyst Caleb Franzen recently made a point that's worth considering,

Oversold readings in bull markets are bullish.

Oversold readings in bear markets aren't bullish.

Meanwhile, others, like MilkRoad, agree with Bittel,

“Short term oversold signals have to be interpreted inside the liquidity and business cycle.

If conditions keep improving and money keeps flowing back into markets, these oversold dips tend to work higher over time, even if it’s messy along the way[…] We will go higher.”

Mentioned in this article

Bitcoin’s (BTC) recent price weakness has revived investors’ concerns of a deeper downturn, but several market analysts argue that an extended correction may be more constructive over the longer term.

Key takeaways:

Analysts say Bitcoin’s downside risk is centered around $65,000 to $75,000.

A potential three-day bullish divergence is forming, a setup that could align with a local bottom once momentum stabilizes.

Supply rotation and oversold conditions define BTC’s current price actionCrypto trader Jackis said that the current move is a macroeconomic range for 2025, noting that even a decline to $70,000 would not resemble prior bear markets. Unlike 2022 or early 2024, the current drawdown lacks systemic macro-driven risk-off pressure, instead reflecting a rotation of supply from early holders to institutional participants.

Meanwhile, market analyst Jelle highlighted a potential bullish divergence forming on Bitcoin’s three-day chart. The previous three-day divergences in this cycle have coincided with local bottoms, although the trader said that a confirmation requires additional time and consolidation.

Bitcoin 3-day bullish divergence possibility. Source: Jelle/XJulien Bittel, the head of macro research at Global Macro Investor, reinforced this view by pointing to Bitcoin’s historical behavior following oversold RSI readings below 30.

According to data, Bitcoin tends to track a well-defined recovery path after such conditions emerge. While short-term volatility remains likely, Bittel argued that bases often take time to form and are usually accompanied by choppy price action before a sustained uptrend resumes.

Bittel contends that the traditional four-year halving cycle is no longer the dominant driver of Bitcoin’s price behavior. Instead, extended debt refinancing cycles and evolving liquidity dynamics suggest the current market structure could persist well into 2026.

Bitcoin’s market path with RSI dropped below 30. Source: Julien Bittel/XLonger Bitcoin cycles favor flatter but higher returnsJurrien Timmer, the director of Global Macro at Fidelity, placed the current phase within a broader wave structure spanning 2022 to 2025. That period has already delivered a 105% compound annual growth rate (CAGR) over 145 weeks, closely tracking long-term regression models.

While Timmer acknowledged that Bitcoin may still experience a deeper correction into the $65,000 to $75,000 range in 2026, he emphasized that such zones have acted as strong buy zones.

Bitcoin wave 6 price target analysis. Source: Jurrien Timmer/XLooking further ahead, Timmer expects future cycles to evolve with flatter slopes as adoption matures. Even so, the price modelling suggests a potential path toward $300,000 by 2029 if a new expansion phase emerges.

In this context, corrective phases may serve as the foundation for Bitcoin’s next structural advancement.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

MINNEAPOLIS--(BUSINESS WIRE)--The Board of Directors of Xcel Energy Inc. (NASDAQ: XEL) today declared a quarterly dividend on its common stock of 57 cents per share. The dividends are payable January 20, 2026, to shareholders of record on December 29, 2025. Xcel Energy is a major U.S. electricity and natural gas company, with operations in 8 Western and Midwestern states. Xcel Energy provides a comprehensive portfolio of energy-related products and services to 3.9 million electricity customers.

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the sector held up well, driven by solid momentum from new drug approvals and encouraging pipeline progress. Given the continuous need for innovative medical treatments (regardless of the state of the economy), the dynamic biotech industry will continue to capture investors’ interest going forward.

2025 saw a surge in mergers and acquisitions (M&A) after a lull in 2024, given the changing landscape and the spotlight on AI-driven drug discovery. Large pharmaceutical and biotechnology companies continually expand their product portfolios and pipelines through strategic collaborations and acquisitions to adapt their business models amid rising generic competition for key drugs. As a result, smaller biotechs leveraging breakthrough technologies are increasingly in the spotlight, helping drive momentum across the broader sector.

Biotech companies like Arcutis Biotherapeutics (ARQT - Free Report) , Amicus Therapeutics (FOLD - Free Report) , ANI Pharmaceuticals (ANIP - Free Report) , Tango Therapeutics, Inc. (TNGX - Free Report) and Pacira Biosciences (PCRX - Free Report) are poised to outperform the sector. 

This industry includes biopharmaceutical and biotech stocks like Amgen, Inc. (AMGN).
The Zacks Biomedical and Genetics industry comprises biopharmaceutical and biotechnology companies that develop high-profile drugs utilizing groundbreaking technology. These biologically processed drugs, which address virology, neuroscience, metabolism and rare diseases, are manufactured using live organisms.

As technology becomes increasingly crucial to improving global health, biotech companies strive to utilize innovative technologies to rapidly develop breakthrough treatments. Several companies in this field are developing drugs and vaccines utilizing modern technology. Given the dynamic and evolving nature of technology, the sector seems riskier than the large-cap pharma or drug industry.

4 Trends Shaping the Future of the Biotech Industry
Innovation and Execution Hold the Key: The primary focus in the biotech industry is on the performance of high-profile drugs and innovative pipeline development, as only a handful of companies in this industry have approved drugs in their portfolios. Most companies spend millions and billions of dollars to create a drug with path-breaking technology, resulting in significant research and development expenditures. The recent spotlight on the usage of AI technology for drug discovery will propel further investment in this industry. Precision medicine, also known as personalized medicine, is another rapidly evolving field in the industry.

On the other hand, successful commercialization is crucial for higher drug uptake, as smaller biotechs often lack the necessary funds and expertise to reach the target population. This prompts collaboration deals with either pharma or biotech bigwigs, wherein sales are shared or royalties are received.

Sometimes, approved treatments come with side effects that emerge over time, and the uptake may fail to meet expectations. Hence, it takes several years before a biotech company turns profitable. Moreover, it may take quite a few years for any newly approved drug to contribute to its company’s top line.

M&A in the Spotlight: Consolidation has long been a key theme in the pharma and biotech industry, as leading companies continually seek to diversify their revenue streams amid declining sales from their flagship drugs. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery.

Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios/pipelines in their respective core areas or emerging fields. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are now being eyed.

Johnson & Johnson is set to acquire clinical-stage biotechnology company, Halda Therapeutics OpCo. The acquisition provides Johnson & Johnson with a highly differentiated clinical-stage treatment for prostate cancer. Swiss pharma bigwig Novartis, too, has been on an acquisition spree. Novartis recently announced that it will acquire Avidity Biosciences, Inc. for $12 billion to strengthen its late-stage neuroscience pipeline. Avidity is developing RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs) for serious, genetic neuromuscular diseases. Sanofi earlier acquired Blueprint Medicines for $9.5 billion to expand its portfolio in rare immunological diseases.

The recent spotlight on the usage of AI technology for drug discovery should lure further investment in this industry.

New Drug Approvals Boost Prospects: New drug approvals accelerated in 2025 as most companies aim to diversify their portfolios. The FDA has approved more than 40 drugs in 2025 so far.

Pipeline Setbacks & Potential Tariffs Weigh on Outlook: Pipeline setbacks are key deterrents for biotech companies, given the exorbitant cost of developing drugs using expensive technology. Most drugs/therapies take years to gain a regulatory nod. An unfavorable outcome from a crucial trial on a promising candidate is a huge setback, particularly for smaller biotechs, which are mostly one-trick ponies. The leading biotechs face other headwinds, including declining sales of high-profile drugs due to intensifying competition.

Many big pharma/biotech companies have sizeable production units outside the country and imposition of tariffs will increase their costs, thereby shrinking margins. Moreover, ongoing geopolitical tensions remain a headwind. 

Zacks Industry Rank Indicates Bright Prospects
The group’s Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks.

The Zacks Biomedical and Genetics industry currently carries a Zacks Industry Rank #89, which places it among the top 37% of more than 243 Zacks industries. The rank reflects a bright outlook for the space, driven by consistent demand for better medical treatments despite the challenging macroenvironment. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Before we present a few biotech stocks that are well-positioned to beat the industry based on a strong portfolio/pipeline, let’s take a look at the industry’s stock market performance and current valuation.

Industry Versus S&P 500 & Sector
The Zacks Biomedical and Genetics industry is a 674-stock group within the broader Zacks Medical sector. It has outperformed both the Zacks Medical sector and the S&P 500 composite sector in the last six months.

The stocks in this industry have gained 22.1% in the last six months compared with the Zacks Medical sector’s growth of 12.5% and the S&P 500 composite’s rise of 16.5% in the said time frame.

One Year Price Performance

Industry's Current Valuation
Since most companies in the biotech sector do not have approved drugs, valuing these becomes a complex process. On the basis of the trailing 12-month price-to-sales ratio (P/S TTM), which is commonly used for valuing biotech companies with approved portfolios of drugs, the industry is currently trading at 2.47X compared with the S&P 500’s 5.96X and the Zacks Medical sector's 2.66X.

Over the past five years, the industry has traded as high as 4.31X, as low as 1.86X and at a median of 2.65X, as depicted in the chart below.

5 Biotech Stocks Worth Buying
Amicus Therapeutics has put up a stellar performance. Lead marketed drug, Galafold, has shown solid uptake and is witnessing continued demand. Galafold is approved for treating Fabry disease. Amicus’ efforts to expand Galafold's label should propel sales further. The recent settlement of the Galafold patent litigation with Teva wards off generic competition in the near term. The FDA approval of Pombiliti + Opfolda for treating Pompe disease is a significant boost to the portfolio.

FOLD currently carries a Zacks Rank #1 (Strong Buy). Shares of FOLD have soared 90.2% in the past six months. The Zacks Consensus Estimate for 2025 EPS has increased five cents to $0.36 in the past 90 days.

Price and Consensus: FOLD

ANI Pharmaceuticals is a diversified biopharmaceutical company with two focal areas – rare diseases and generics. The company’s rare disease franchise has emerged as a major growth catalyst in 2025 on the back of strong performance of ACTH-based injection Cortrophin Gel, whose sales surged 70% year over year to $236 million in the first nine months of 2025.

The acquisition of Alimera Sciences, Inc., in 2024 added a growing and durable franchise, Iluvien for (diabetic macular edema) and Yutiq (for the treatment of non-infectious uveitis affecting the posterior segment of the eye) to its portfolio. 
The company has a presence in the generics market as well.

ANIP’s shares have gained 50.3% in a year. Earnings estimates for 2025 have increased 27 cents to $7.56 in the past 60 days. ANIP currently carries a Zacks Rank #1.

Price and Consensus: ANIP

Arcutis Biotherapeutics, a commercial stage company, has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases — plaque psoriasis, seborrheic dermatitis and atopic dermatitis. The company’s lead product Zoryve (roflumilast) cream 0.3% for the treatment of plaque psoriasis has been performing well. Consistent label expansion of Zoryve has boosted sales. Zoryve topical foam 0.3% is approved for the treatment of seborrheic dermatitis while Zoryve cream 0.15% is approved for the treatment of mild to moderate atopic dermatitis.

ARQT currently carries a Zacks Rank #2 (Buy). Estimates for 2025 loss per share have narrowed to $0.24 from $0.44 in the past 60 days. Shares have skyrocketed 108.7% in the past six months.

Price and Consensus: ARQT

Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicine for oncology. The company is currently developing two MTAP-deleted selective PRMT5 inhibitors — vopimetostat (TNG462) for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM).

The pipeline progress has been encouraging. In October 2025, the company reported positive data from the ongoing phase I/II study of vopimetostat in patients with MTAP-deleted selective cancers, demonstrating clinical activity across multiple cancer types with a favorable safety and tolerability profile to date.

Shares of this Zacks Rank #2 company have surged 86.7% in the past six months. Estimates for 2025 loss per share have narrowed 16 cents to $0.89 in the past 60 days.

Price and Consensus: TNGX

Pacira BioSciences’ lead drug, Exparel, maintains momentum for the company. PCRX is also looking to further expand Exparel’s label. The drug has also been included in a specialized reimbursement scheme, which has increased patient access and compliance, boosting sales. The settlement of the Exparel patent litigation with several generic players is also a win, as it protects its exclusivity in the United States at least until 2030. The ongoing phase II study on PCRX-201 for OA knee pain is encouraging.

This Zacks Rank #2 company has gained 36.4% in a year. Earnings estimates for 2025 have increased 5 cents to $2.90 per share in the past 90 days.

Price and Consensus: PCRX

You can see the complete list of today’s Zacks #1 Rank stocks here. 

Key Takeaways PG uses deep consumer insights and science-led innovation to drive performance and value.Integrated innovation across brands supports organic growth, pricing strength and category expansion.PG's Q1 FY26 operating margin rose 40 bps, aided by 230 bps of gross productivity savings.
The Procter & Gamble Company (PG - Free Report) has been making steady, consumer-centric innovations by leveraging deep consumer insights to develop products that more effectively meet their everyday needs. This insight-driven approach enables PG to innovate with precision. Its innovation model prioritizes scalable, science-led enhancements that improve performance, convenience and value.

The company looks to reinforce the integration of its entire vectors of superiority, with robust innovation program. This includes developing stronger core brand propositions and expanding into larger adjacencies and formats to enrich consumer delight across both core and premium offerings. PG continues to invest in innovation and demand creation to enhance consumer value and support category growth.

By aligning R&D, manufacturing and go-to-market execution around consumer needs, PG’s ongoing, insight-led innovations continue to drive organic growth and pricing strength, hence aiding margins and bolstering its leadership in a highly competitive global consumer staples landscape. On a currency-neutral basis, the operating margin increased 40 basis points (bps) year over year in first-quarter fiscal 2026. The operating margin included solid productivity savings of 230 bps.

At the core, PG’s innovation strategy remains a vital part of its long-term growth and margin resilience, designed to strengthen brand leadership while managing cost inflation, private-label competition and evolving consumer preferences. Certainly, PG’s innovation push is well positioned to protect margins in FY26, though it might not lead to further expansion. Innovation, paired with productivity, premiumization and disciplined pricing, will help the company absorb cost pressures and keep margins broadly intact.

PG’s Peers: How Are CL & CLX Innovating?Colgate-Palmolive Company (CL - Free Report) and The Clorox Company (CLX - Free Report) are competing with PG.

Colgate’s science-led innovation pipeline, including the global relaunch of Colgate Total, continued progress in premium oral care and Hill’s robust therapeutic portfolio, remains a key driver of category growth and brand penetration. CL’s premiumization efforts focus on offering top-quality, advanced products that deliver better performance. This includes innovations like high-end oral care solutions, specialized toothpastes, electric toothbrushes and premium personal and home care products. Colgate’s balanced strategy of driving premium innovation while sharpening value offerings positions it well to navigate near-term challenges and deliver growth.

Clorox focuses on delivering greater value to consumers through ongoing innovation, enhanced product performance and smart pricing. CLX’s product innovations, coupled with comprehensive margin-management efforts, further help it focus on delivering superior value to consumers through brand-building initiatives and aid margins. This helps Clorox set its brands apart from private-label competitors and support long-term growth.

PG’s Price Performance, Valuation and EstimatesProcter & Gamble’s shares have lost 14.1% in the past year compared with the industry’s 15.1% decline.

Image Source: Zacks Investment Research

From a valuation standpoint, PG is trading at a forward price-to-earnings ratio of 20.21X compared with the industry’s average of 18.17X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for PG’s fiscal 2026 and fiscal 2027 EPS reflects year-over-year growth of 2.6% and 5.5%, respectively. The company’s EPS estimate for fiscal 2026 has been stable while that of fiscal 2027 has moved southward in the past 30 days.

Image Source: Zacks Investment Research

Key Takeaways SDRL won multiple drillship contracts across the Gulf of America and Angola, expanding its contract backlog.SDRL said the West Neptune contract with LLOG Exploration adds about $48 million to its contract backlog.Seadrill extended Sonangol Quenguela's Angola operations, keeping the rig active until Feb 2027.
Seadrill Limited (SDRL - Free Report) , a U.S.-based offshore drilling contractor, has secured multiple contracts for the drillships in its rig fleet. These contracts contribute to Seadrill’s backlog, enabling it to establish strong relationships with new and existing customers.

Seadrill mentioned that its West Neptune drillship has secured a four-month contract in the Gulf of America with LLOG Exploration. The contract is expected to start in direct continuation of the drillship’s current assignment. SDRL has also stated that this contract will add approximately $48 million to the company’s backlog. The West Neptune drillship is a seventh-generation ultra-deepwater dual activity drillship with a maximum drilling depth of up to 37,500 feet.

The second contract is for the Sevan Louisiana circular drillship in the Gulf of America. An undisclosed operator has hired the Sevan Louisiana drillship for a two-month assignment. The contract is expected to begin immediately after the drillship ends its assignment with Walter Oil and Gas. Notably, this deal marks the first deployment of Trendsetter’s well-intervention equipment in the region. This highlights a new technical capability being utilized in the Gulf of America, enhancing the efficiency of deepwater operations. The Sevan Louisiana drillship was built in 2013 and features a Sevan 650 design. It has a maximum drilling depth of 35,000 feet and can operate in water depths of up to 10,000 feet.

SDRL also mentioned a third deal for the Sonangol Quenguela drillship in Angola, Africa. This deal marks an extension of the drillship’s operations in Angola, as the operator exercised a five-month option to prolong its stay in the region by approximately 10 months. The drillship will continue its operations in Angola till February 2027. The Sonangol Quenguela is a seventh-generation ultra-deepwater drillship with prior operating experience in West Africa.

Seadrill mentioned that its ability to secure contracts in direct continuation of existing ones enables it to avoid white space, which is the time between two contracts when a rig remains idle, amid challenging market conditions. These deals enable the company to build a strong contract backlog into 2027 and beyond, ensuring revenue visibility in the future.

SDRL’s Zacks Rank and Key Picks

SDRL currently has a Zacks Rank #5 (Strong Sell).

Some top-ranked stocks from the energy sector are Oceaneering International (OII - Free Report) , Canadian Natural Resources Ltd. (CNQ - Free Report) and FuelCell Energy (FCEL - Free Report) . While Oceaneering currently sports a Zacks Rank #1 (Strong Buy), Canadian Natural Resources and FuelCell carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Oceaneering International delivers integrated technology solutions across all stages of the offshore oilfield lifecycle. The company is a leading provider of offshore equipment and technology solutions to the energy industry. OII’s proven ability to deliver innovative, integrated solutions supports ongoing client retention and new business opportunities, ensuring steady revenue growth.

Canadian Natural Resources is one of the largest independent energy companies in Canada engaged in the exploration, development and production of oil and natural gas. The company boasts a diversified portfolio of crude oil, natural gas, bitumen and synthetic crude oil. It has delivered 25 consecutive years of dividend increases, one of the longest streaks among global oil producers.

FuelCell Energy is a clean energy company offering low-carbon energy solutions. It produces power using flexible fuel sources such as biogas, natural gas and hydrogen. The company designs fuel cells that generate electricity through an electrochemical process that combines fuel with air, reducing carbon emissions and minimizing the environmental impact of power generation. As such, FCEL is anticipated to play a crucial role in the energy transition by enabling industries and communities to shift from traditional fossil fuels to low-carbon alternatives.

Mercer to lead sales and marketing for MasterCraft Boat Holdings’ pontoon brands

December 17, 2025 15:27 ET

 | Source:

MasterCraft Boat Holdings, Inc.

OWOSSO, Mich., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Crest Pontoons and Balise Pontoons, subsidiaries of MasterCraft Boat Holdings, Inc (NASDAQ: MCFT) proudly announce the appointment of Mike Mercer as Vice President of Sales & Marketing for both brands. In this role, Mercer will lead sales, dealer development, and marketing across Crest and Balise, supporting long-term growth and enhanced dealer engagement.

Mercer brings nearly three decades of marine industry experience spanning dealership operations and regional and national sales leadership, most recently serving in a senior sales and marketing role at a global marine manufacturer. His background bridging retail experience with OEM strategy equips him to strengthen for Crest and Balise dealers.

“Mike’s broad industry experience and leadership ability make him an outstanding fit for Crest and Balise,” said Mike O’Connell, SVP MasterCraft Boat Holdings and President Crest & Balise, “Both brands have strong momentum heading into the 2026 model year, and Mike will play a key role in enhancing dealer support, advancing our market strategy, and accelerating growth across the pontoon division.”

In addition to Crest–an established industry leader for nearly 70 years–Mercer will also help expand Balise’s dealer network and position the brand for continued growth as it enters its second boat show season.

“I’m honored to join Crest and Balise at such an exciting time,” said Mercer. “Crest has a legacy of quality and reliability, while Balise is redefining what’s possible in the luxury segment. Having first visited the Crest facility nearly 30 years ago as a dealership salesman, it’s impressive to see how the brand and product have evolved. I’m excited to partner with our dealers and teams as we build on each brand’s strengths and prepare for an exciting boat show season ahead.”

As part of this leadership alignment, Esteban Siegert will continue with the organization in a dedicated sales leadership role focused exclusively on Balise, supporting the brand’s continued growth and dealer expansion.

About MasterCraft Boat Holdings, Inc.:
Headquartered in Vonore, TN, MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) is a leading innovator, designer, manufacturer, and marketer of premium recreational powerboats through its three brands, MasterCraft, Crest, and Balise. For more information about MasterCraft Boat Holdings, please visit Investors.MasterCraft.com, www.MasterCraft.com, www.CrestPontoonBoats.com, and www.BalisePontoonBoats.com

Media Contact:

Kaitlin Riley
Senior Marketing Coordinator
Crest & Balise Pontoons
[email protected]

HomeStock IdeasLong IdeasTech 

SummaryCoreWeave is upgraded to a strong buy after a 40%+ stock decline, citing overblown concerns and a compelling risk/reward setup.CRWV faces near-term data center delays and profitability pressures, but demand remains exceptionally robust, as evidenced by a $55.6B revenue backlog.Despite lowering FY revenue and operating income guidance, long-term growth prospects remain intact, with supply—not demand—constraining results.Valuation has collapsed to a forward P/S of 6.75, creating a significant opportunity versus peers and prior levels. onurdongel/iStock via Getty Images

In late September, I initiated coverage on CoreWeave, Inc. (CRWV) with a buy rating. Demand for infrastructure was determined to be robust, the valuation pullback was attractive, and perhaps most importantly, the company's agreement with Nvidia (

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRWV, NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Analyst's family has a beneficial long position in the shares of NVDA.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Given the murky macroeconomic landscape, navigating the fixed income markets can be a tricky undertaking. MFS Co-CIO of Fixed Income, Pilar Gómez-Bravo, provided valuable insights on the current fixed income environment in an interview: Navigating the Fixed Income Valuation Conundrum.

While markets have been doused in uncertainty stemming from tariffs, geopolitical tensions, changing interest rate policy, and other factors, the broader fixed-income market has been relatively resilient. This is especially true for fixed-income assets with stronger credit fundamentals, such as investment-grade debt.

“If you look for system-wide indicators of stress or if you look at the investment-grade markets, we’re seeing a more broadly stable environment,” said Gómez-Bravo, noting that credit risks are “heightened, but contained for now.”

Gómez-Bravo noted that there are four specific macro risks: growth, inflation, monetary policy, and fiscal policy. The confluence of all four factors will continue to play a role in determining how the fixed income market will unfold from a forward-looking perspective.

“There’s still a lot of unpredictability in the global stage,” Gómez-Bravo summarily said, but added that it’s still an exciting time for the fixed income markets, where there are still opportunities to exploit.

That said, investors don’t need to stay on the sidelines due to unpredictability and uncertainty. This is where an actively managed fund can benefit a portfolio.

2 Active Fixed Income Options
As noted in the interview with Gómez-Bravo, systematic risks are a major concern for fixed income markets. Furthermore, there are idiosyncratic risks inherent in specific sub-sectors of the bond market. This makes an active management strategy a necessity. With that, MFS offers a pair of funds investors should consider for fixed-income exposure: the MFS Active Core Plus Bond ETF (MFSB) and the MFS Active Intermediate Muni Bond ETF (MFSM).

Per the MFSB fact sheet, the fund uses a “primarily investment-grade bond strategy that integrates macro, bottom-up, and technical perspectives in an effort to add value through sector and quality allocation, security selection, and also duration/yield curve decisions. The fund could serve as a standalone exposure for investors looking for a core bond alternative.

Municipal bonds this year have attracted investor attention for their strong credit fundamentals and yields. Of course, the federal tax-free income is also a draw. MFSB exploits inefficiencies in municipal credit markets via active sector, quality, and security selection. Exposure focuses on munis with intermediate maturities for added yield opportunities during this rate-cutting cycle. Adding active management to a nuanced muni market means the fund’s portfolio managers can look to maximize opportunities in munis for income as well as price appreciation.

For cost-conscious investors, both funds have expense ratios of just 34 basis points, or $34 per $10,000 invested.

For more news, information, and strategy, visit our Portfolio Construction Content Hub.

Earn free CE credits and discover new strategies

Kitco News

The Leading News Source in Precious Metals

Kitco NEWS has a diverse team of journalists reporting on the economy, stock markets, commodities, cryptocurrencies, mining and metals with accuracy and objectivity. Our goal is to help people make informed market decisions through in-depth reporting, daily market roundups, interviews with prominent industry figures, comprehensive coverage (often exclusive) of important industry events and analyses of market-affecting developments.

MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NASDAQ: FISV), a global leader in payments and financial technology, has completed its acquisition of StoneCastle Cash Management, expanding its ability to deliver innovative insured deposit funding solutions. By integrating StoneCastle's institutional deposit network with the Fiserv ecosystem, including core account processing, digital banking, and payments platforms, Fiserv is creating a differentiated offering that helps financial institutions optimi.

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

Investors have until December 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Synopsys securities. The class action is pending in the U.S. District Court for the Northern District of California and is captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410.

Why Was Synopsys Sued for Securities Fraud?

Synopsys provides design automation software products used to design and test integrated circuits. The Company's Design IP segment, which provides pre-designed silicon components to semiconductor companies, has been the Company's fastest-growing segment, growing from 25% of its revenue in 2022, to 31% in 2024.

During the relevant period, Synopsys told investors that its customers "rely on Synopsys IP to minimize integration risk and speed time to market" and that it was seeing "strength in Europe and South Korea." Synopsys also stated it was "continuing to develop and deploy[] AI into our products and the operations of our business."

As alleged, in truth, the Company's Design IP customers began to require additional customization for IP components, which was deteriorating the economics of its Design IP business and jeopardizing its business model.

The Stock Declines as the Truth Is Revealed

On September 9, 2025, Synopsys released its Q3 2025 financial results, revealing its "IP business underperformed expectations." The Company reported revenue for its Design IP segment of $425.9 million, a 7.7% decline year-over-year and net income of $242.5 million, a 43% year-over-year decline. The Company revealed that its Design IP customers require "more and more customization," which "takes longer" and requires "more resources." As a result, the Company stated it was having "an ongoing dialogue with our customers" regarding changing its business model. This news caused the price of Synopsys stock to fall $217.59 per share, or nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025.

Click here for more information: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

What Can You Do?

If you invested in Synopsys you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277917

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Stride securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned MacMahon v. Stride, Inc., et al., No. 1:25-cv- 02019.

Why is Stride Being Sued For Securities Fraud?

Stride is an education technology company that provides an online platform to students throughout the U.S. During the relevant period, Stride stated it was seeing "increasing growth in our business," "in-year strength in demand" for its products and services, and that its customers and potential customers "continue to choose us in record numbers."

As alleged, in truth, Stride had inflated enrollment numbers by retaining "ghost students," ignored compliance requirements for its employees, and had "poor customer experience" that resulted in "higher withdrawal rates," "lower conversion rates," and had driven students away.

Why did Stride's Stock Drop?

On September 14, 2025, a report stated that a complaint had been filed against Stride for fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct. It claimed Stride inflated enrollment numbers by retaining "ghost students" on rolls to secure state funding and ignored compliance requirements, including background checks and licensure laws for its employees. This news caused the price of Stride stock to drop $18.60 per share, or more than 11%, from a closing price of $158.36 per share on September 12, 2025, to $139.76 per share on September 15, 2025.

Then, on October 28, 2025, Stride admitted that "poor customer experience" resulted in "higher withdrawal rates," "lower conversion rates," and drove students away. Stride estimated the impact caused approximately 10,000-15,000 fewer enrollments and stated that, because of this, its outlook is "muted" compared to prior years. This news caused the price of Stride stock to drop $83.48 per share, or more than 54%, from a closing price of $153.53 per share on October 28, 2025, to $70.05 per share on October 29, 2025.

Click here for more information: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

What Can You Do?

If you invested in Stride you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277916

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company's fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its "inherent strength" and "the underlying momentum in our strategy." The Company also stated on May 20, 2025, that it was seeing "normal stock levels" among its customers and that it was "seeing performance in the month to date as we would expect."

As alleged, in truth, the Company's North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered "in April through May" as customers "made efforts to return to more normal inventory levels[.]" The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

On November 17, 2025, James Hardie announced that Rachel Wilson had decided to step down from her role as CFO.

Click here for more information: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277914

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

Investors have until January 5, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota and is captioned City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247.

Why is Inspire Being Sued for Securities Fraud?

Inspire develops and manufactures an implantable medical device for the treatment of sleep apnea. The latest version of the device is the Inspire V. The company announced FDA approval of Inspire V on August 2, 2024.

During the relevant period, Inspire repeatedly assured investors that it had taken all necessary steps to facilitate the launch of Inspire V and that it would launch the device as soon as sufficient inventory was available to meet supposedly high demand.

As alleged, in truth, Inspire failed to take basic steps to prepare clinicians and payors for the rollout, resulting in significant delays in adoption of the device. Moreover, the launch suffered from weak demand, as many customers already had excess inventory of the company's older devices.

Why did Inspire's Stock Drop?

On August 4, 2025, Inspire disclosed that the Inspire V launch was facing an "elongated timeframe" and as a result, it was reducing its 2025 earnings per share guidance by more than 80%. The company attributed the longer timeframe to a number of previously undisclosed factors including that many implanting centers "did not complete the training, contracting and onboarding required prior to the purchase and implant of Inspire V," that certain "software updates for claims submissions and processing did not take effect until July 1, [2025]" which meant implanting centers could not bill for procedures until that date, and that demand for the Inspire V was poor because Inspire's customers had a backlog of older versions of the company's device.

On this news, the price of Inspire stock dropped $42.04 per share, or more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

What Can You Do?

If you invested in Inspire you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277911

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

In December, shares of Marvell Technology NASDAQ: MRVL have taken one step forward and three steps back. The semiconductor company put out a strong earnings report and outlook on Dec. 2.